Eptifibatide Accord
Antiplatelet Agent for Acute Coronary Syndrome and Coronary Intervention
Quick Facts About Eptifibatide Accord
Key Takeaways About Eptifibatide Accord
- Hospital-only medication: Eptifibatide Accord is administered exclusively in hospital settings by trained healthcare professionals via intravenous injection and infusion
- Rapid-acting antiplatelet: Achieves over 80% platelet aggregation inhibition within minutes, with effects wearing off 4–8 hours after stopping the infusion
- Used with aspirin and heparin: Always given as part of a combination antiplatelet and anticoagulant regimen in acute coronary syndrome
- Bleeding is the main risk: The most common side effect is bleeding, ranging from minor bruising to serious haemorrhage – close monitoring is essential
- Renal dose adjustment: Patients with moderate kidney impairment require a reduced infusion rate; the drug is not recommended in severe renal failure
What Is Eptifibatide Accord and What Is It Used For?
Eptifibatide Accord is a platelet aggregation inhibitor (antiplatelet agent) that prevents blood clots by blocking the glycoprotein IIb/IIIa receptor on the surface of platelets. It is used in adults with signs of serious cardiac insufficiency, defined as spontaneous and recent chest pain with ECG changes or biological abnormalities.
Eptifibatide belongs to the glycoprotein (GP) IIb/IIIa receptor antagonist class of antiplatelet drugs. The GP IIb/IIIa receptor is the most abundant integrin on the platelet surface and serves as the final common pathway for platelet aggregation. When platelets are activated – whether by arterial injury, plaque rupture, or other stimuli – the GP IIb/IIIa receptor undergoes a conformational change that allows it to bind fibrinogen and von Willebrand factor, cross-linking adjacent platelets and forming a thrombus (blood clot). Eptifibatide competitively and reversibly binds to this receptor, preventing the cross-linking process and thereby inhibiting platelet aggregation.
Eptifibatide is a synthetic cyclic heptapeptide modelled on the Lys-Gly-Asp (KGD) sequence found in the venom of the southeastern pygmy rattlesnake (Sistrurus miliarius barbouri). This KGD sequence specifically targets the GP IIb/IIIa receptor with high affinity, providing potent and selective antiplatelet activity. Unlike aspirin and clopidogrel, which act on earlier steps of the platelet activation cascade, eptifibatide blocks the final step of platelet aggregation, making it one of the most effective antiplatelet agents available.
Clinically, Eptifibatide Accord is primarily indicated for two related scenarios. First, it is used in the acute management of unstable angina and non-ST-segment elevation myocardial infarction (NSTEMI) – collectively known as acute coronary syndrome (ACS) – where it is administered alongside aspirin and unfractionated heparin to reduce the risk of myocardial infarction and death. Second, it is used in patients undergoing percutaneous coronary intervention (PCI), including coronary angioplasty and stent placement, to prevent thrombotic complications during and after the procedure.
The landmark PURSUIT trial (Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy), published in The New England Journal of Medicine, demonstrated that eptifibatide significantly reduced the composite endpoint of death or non-fatal myocardial infarction at 30 days compared to placebo in patients with ACS. The ESPRIT trial further confirmed its efficacy in patients undergoing PCI with coronary stenting, showing a significant reduction in ischaemic events.
Eptifibatide is typically administered in a cardiac care unit (CCU), coronary care unit, or catheterisation laboratory. It is given intravenously and is not available in oral form. The drug is provided as a ready-to-use, clear, colourless solution in a 100 ml glass vial. The solution must be inspected before use and should not be administered if it contains particles or is discoloured.
What Should You Know Before Receiving Eptifibatide Accord?
Before receiving eptifibatide, your healthcare team must review your complete medical history, including any bleeding disorders, recent surgery, or stroke history. The drug is contraindicated in several conditions, and your doctor will perform blood tests before and during treatment to ensure safety.
Contraindications
You must not receive Eptifibatide Accord if any of the following conditions apply:
- Allergy to eptifibatide or any other ingredient in this medicine (citric acid monohydrate, sodium hydroxide, water for injections)
- Recent gastrointestinal or genitourinary bleeding – if you have experienced bleeding from the stomach, intestines, bladder, or other organs within the past 30 days (excluding menstrual bleeding), for example if you have noticed abnormal blood in your stool or urine
- Stroke within the past 30 days or any history of haemorrhagic stroke – also inform your doctor if you have ever had a stroke of any kind
- Brain tumour or any disease affecting the blood vessels of the brain, including arteriovenous malformations or aneurysms
- Major surgery or severe trauma within the past 6 weeks
- Known bleeding disorder or history of clinically significant bleeding diathesis
- Thrombocytopenia (low platelet count, below 100,000/mm³) or a history of thrombocytopenia associated with GP IIb/IIIa inhibitors
- Severe uncontrolled hypertension (systolic blood pressure above 200 mmHg or diastolic above 110 mmHg despite treatment)
- Severe kidney or liver disease – eptifibatide is primarily excreted by the kidneys and is not recommended in patients with creatinine clearance below 30 mL/min
- Concurrent use of another GP IIb/IIIa inhibitor (such as abciximab or tirofiban)
Tell your doctor if you have ever had any of these conditions. If you have any questions, ask your doctor, hospital pharmacist, or nurse for advice before receiving eptifibatide.
Warnings and Precautions
Eptifibatide Accord is recommended only for use in adult hospitalised patients on cardiology wards or in catheterisation laboratories. It is not intended for use in children or adolescents under 18 years of age. The following precautions are important:
Before and during treatment with Eptifibatide Accord, blood samples will be taken as a safety measure to limit the risk of unexpected bleeding. These tests typically include a complete blood count (CBC) with platelet count, activated clotting time (ACT), activated partial thromboplastin time (aPTT), and prothrombin time (PT). Your haemoglobin and haematocrit levels will also be monitored to detect occult bleeding.
While receiving Eptifibatide Accord, you will be closely monitored for signs of unusual or unexpected bleeding. This includes monitoring of vascular access sites (such as where catheters are inserted), as well as systemic signs of bleeding. The risk of bleeding is increased in patients who are elderly, have a low body weight, are female, or have mildly reduced kidney function.
If clinically significant bleeding occurs that cannot be controlled with standard measures, the eptifibatide infusion should be discontinued immediately. Because eptifibatide’s antiplatelet effect is reversible, platelet function typically returns to near-normal within 4–8 hours of stopping the infusion, which is a significant advantage over irreversible GP IIb/IIIa inhibitors.
Pregnancy and Breastfeeding
Eptifibatide Accord is generally not recommended for use during pregnancy. The safety of eptifibatide in pregnant women has not been established through adequate clinical studies. If you are pregnant, think you may be pregnant, or are planning to become pregnant, inform your doctor immediately. Your doctor will carefully weigh the potential benefits of treatment against the risks to your unborn baby.
If you are breastfeeding, you should discontinue breastfeeding during the treatment period. It is not known whether eptifibatide is excreted in human breast milk, and a risk to the nursing infant cannot be excluded.
Sodium Content
This medicine contains 172 mg sodium (the main component of table salt) per infusion vial. This is equivalent to 8.6% of the recommended maximum daily sodium intake for an adult. This should be taken into account for patients on a controlled sodium diet.
How Does Eptifibatide Accord Interact with Other Drugs?
Eptifibatide significantly increases bleeding risk when combined with other anticoagulants, antiplatelet agents, and thrombolytics. While it is routinely given with aspirin and heparin under controlled hospital conditions, combining it with other blood-thinning agents requires careful medical supervision and dose adjustments.
To avoid the risk of interactions with other medicines, you should tell your doctor, hospital pharmacist, or nurse about any medications you are currently taking, have recently taken, or might be considering taking, including over-the-counter products, herbal supplements, and dietary supplements. The following drugs are of particular clinical significance when used with eptifibatide.
Major Interactions
| Drug | Category | Effect | Recommendation |
|---|---|---|---|
| Warfarin | Oral anticoagulant | Significantly increased risk of major bleeding due to combined anticoagulant and antiplatelet effects | INR must be below 2.0 before eptifibatide initiation; close monitoring essential |
| Thrombolytics (alteplase, tenecteplase) | Fibrinolytic agents | Greatly increased risk of life-threatening haemorrhage | Concurrent use should be avoided; eptifibatide is an alternative strategy to thrombolysis |
| Other GP IIb/IIIa inhibitors (abciximab, tirofiban) | Antiplatelet agents | Extreme risk of uncontrollable bleeding | Contraindicated – never combine two GP IIb/IIIa inhibitors |
| Dipyridamole | Antiplatelet/vasodilator | Additive antiplatelet effect with increased bleeding risk | Avoid combination or use with extreme caution under specialist supervision |
Therapeutic Combinations (Used Under Medical Supervision)
| Drug | Category | Effect | Recommendation |
|---|---|---|---|
| Aspirin (acetylsalicylic acid) | Antiplatelet (COX inhibitor) | Complementary antiplatelet effect; forms part of standard ACS protocol | Standard co-administration at 150–325 mg daily; monitor for bleeding |
| Unfractionated heparin (UFH) | Anticoagulant | Complementary anticoagulant effect; standard combination in ACS and PCI | Target aPTT 50–70 seconds or ACT 200–300 seconds during PCI |
| Clopidogrel | Antiplatelet (P2Y12 inhibitor) | Additive antiplatelet effect from different mechanisms | May be added as part of dual/triple antiplatelet therapy; monitor bleeding closely |
| Ticlopidine | Antiplatelet (P2Y12 inhibitor) | Additive antiplatelet effect; increased bleeding risk | Use with caution; clopidogrel is generally preferred due to better safety profile |
It is important to note that eptifibatide is routinely given alongside aspirin and unfractionated heparin in clinical practice – these combinations have been extensively studied in large clinical trials. However, the combination increases the overall risk of bleeding compared to aspirin and heparin alone, which is why continuous monitoring is essential throughout the treatment period.
What Is the Correct Dosage of Eptifibatide Accord?
Eptifibatide is given intravenously as an initial bolus injection of 180 micrograms/kg followed by a continuous infusion of 2 micrograms/kg/min for up to 72 hours. The dose is calculated based on body weight and adjusted for kidney function.
Eptifibatide Accord is always administered by healthcare professionals in a hospital setting. You will not need to calculate or administer the dose yourself. The following information is provided for your understanding of the treatment you are receiving.
Adults – Acute Coronary Syndrome
Standard Dosing Protocol
Bolus (loading dose): 180 micrograms/kg given as a rapid intravenous injection
Infusion (maintenance dose): 2 micrograms/kg/min as a continuous intravenous infusion
Duration: Up to 72 hours
The treatment is typically continued until hospital discharge or until coronary artery bypass graft (CABG) surgery is performed, whichever comes first. If percutaneous coronary intervention (PCI) is performed during the treatment, the infusion may be continued for up to 96 hours.
Patients with Reduced Kidney Function
Dose Adjustment for Renal Impairment
Moderate renal impairment (creatinine clearance 30–49 mL/min): The bolus dose remains 180 micrograms/kg, but the continuous infusion rate is reduced to 1 microgram/kg/min.
Severe renal impairment (creatinine clearance below 30 mL/min): Eptifibatide is not recommended due to insufficient clinical data and the risk of drug accumulation.
Since eptifibatide is primarily cleared through the kidneys (approximately 50% of the total body clearance), impaired renal function leads to slower drug elimination, higher plasma concentrations, and consequently a greater risk of bleeding.
During Percutaneous Coronary Intervention (PCI)
PCI-Specific Protocol
If catheterisation (PCI) is performed during eptifibatide treatment, the intravenous infusion may be continued for up to 96 hours (an additional 24 hours beyond the standard 72-hour limit). This extended duration provides continued platelet inhibition during the critical period after coronary stenting, when the risk of acute stent thrombosis is highest.
The bolus and infusion rates remain the same as the standard protocol unless kidney function is impaired.
Children and Adolescents
Eptifibatide Accord is not recommended for use in children and adolescents under 18 years of age. There is insufficient clinical evidence on the safety and efficacy of eptifibatide in the paediatric population, and the drug has not been studied in this age group.
Elderly Patients
No specific dose adjustment is required for elderly patients based on age alone. However, elderly patients often have some degree of renal impairment, which may necessitate the reduced infusion rate of 1 microgram/kg/min. Additionally, elderly patients have an increased baseline risk of bleeding, so extra vigilance during monitoring is warranted. Kidney function should always be assessed before starting eptifibatide in older adults.
Overdose
There is limited clinical experience with eptifibatide overdose. However, excessive dosing can lead to severe and potentially life-threatening haemorrhage. In case of suspected overdose, the infusion should be discontinued immediately. Because eptifibatide has a short half-life (approximately 2.5 hours) and its platelet inhibition is reversible, platelet function is expected to recover within 4–8 hours. Platelet transfusion may be considered in severe cases. Contact emergency services or a poison control centre if an overdose is suspected.
What Are the Side Effects of Eptifibatide Accord?
The most common side effect of eptifibatide is bleeding, which occurs in more than 1 in 10 patients. This ranges from minor bleeding at injection sites to major haemorrhage requiring transfusion. Anaemia (reduced red blood cell count) is also very common. Close monitoring with blood tests is performed throughout treatment.
Like all medicines, Eptifibatide Accord can cause side effects, although not everybody experiences them. Because eptifibatide is a potent antiplatelet agent, the primary risk is bleeding. Your healthcare team will perform regular blood tests and closely monitor you for any signs of unexpected or excessive bleeding throughout the duration of treatment.
- Sudden severe bleeding from any site, including the nose, gums, gastrointestinal tract, or urinary tract
- Blood in your vomit, stools (black or red), or urine
- Signs of internal bleeding: sudden severe headache, confusion, vision changes, abdominal pain, or back pain
- Signs of severe allergic reaction: sudden wheezing, facial swelling, hives, difficulty breathing
- Unexplained rapid heartbeat, chest pain, or signs of shock (cold, clammy skin, dizziness)
Very Common
May affect more than 1 in 10 people
- Minor or major bleeding (including blood in urine, blood in stool, blood in vomit, or bleeding during or after procedures)
- Anaemia (decreased red blood cell count, which may cause tiredness and pallor)
Common
May affect up to 1 in 10 people
- Phlebitis (inflammation of a vein, typically at the infusion site)
Uncommon
May affect up to 1 in 100 people
- Thrombocytopenia (decreased platelet count – the very cells needed for blood clotting)
- Decreased blood supply to the brain (cerebral ischaemia)
Very Rare
May affect up to 1 in 10,000 people
- Severe haemorrhage (bleeding inside the abdomen, brain, or lungs)
- Fatal bleeding (extremely rare but documented)
- Severe thrombocytopenia (profound drop in platelet count)
- Skin rash (urticaria/hives)
- Anaphylaxis (sudden severe allergic reaction)
Safety measures to prevent serious bleeding complications include regular blood tests (platelet count, haemoglobin, haematocrit, and coagulation parameters) and careful monitoring by your healthcare team. The catheter insertion site (femoral artery or radial artery) is also checked regularly for signs of local bleeding or haematoma formation.
Other events that may occur in patients requiring this type of treatment are related to the underlying cardiac condition being treated rather than the drug itself. These include rapid or irregular heartbeat (tachyarrhythmia), low blood pressure (hypotension), cardiogenic shock, or cardiac arrest. These are complications of acute coronary syndrome and are not directly caused by eptifibatide.
It is important to report suspected side effects after the medicine has been authorised. This allows continuous monitoring of the medicine’s benefit/risk balance. Healthcare professionals and patients are encouraged to report suspected adverse reactions to their national pharmacovigilance authority or through the European Medicines Agency (EMA) reporting systems.
How Should Eptifibatide Accord Be Stored?
Eptifibatide Accord must be stored in a refrigerator at 2°C to 8°C and kept in the outer carton to protect from light. It should be inspected before use and discarded if the solution contains particles or is discoloured.
As a hospital-only medication, the storage of Eptifibatide Accord is managed by your healthcare institution’s pharmacy. However, the following storage requirements are important for ensuring the quality and safety of the product:
- Temperature: Store in a refrigerator at 2°C–8°C (36°F–46°F). Do not freeze.
- Light protection: Keep the infusion vial in the original outer carton to protect from light. However, the solution does not need to be protected from light during administration.
- Expiry date: Do not use after the expiry date stated on the carton and the infusion vial after “EXP.” The expiry date refers to the last day of the stated month.
- Visual inspection: Before use, inspect the contents of the vial. Do not use if the solution contains visible particles or is discoloured. The solution should be clear and colourless.
- Single use: Any remaining medicine in the vial after use should be discarded. Do not save or reuse partially used vials.
- Disposal: Medicines should not be disposed of via wastewater or household waste. Ask your hospital pharmacist about proper disposal procedures to help protect the environment.
Keep this medicine out of the sight and reach of children, although as a hospital-only product it will be stored in controlled pharmacy areas.
What Does Eptifibatide Accord Contain?
Each millilitre of Eptifibatide Accord 0.75 mg/ml solution for infusion contains 0.75 mg of eptifibatide as the active substance. The other ingredients are citric acid monohydrate, sodium hydroxide, and water for injections.
Active Substance
The active substance is eptifibatide, a synthetic cyclic heptapeptide. Each 100 ml infusion vial contains 75 mg of eptifibatide (0.75 mg per ml). Eptifibatide has a molecular weight of approximately 832 daltons and is composed of six amino acids arranged in a cyclic structure with a mercaptopropionyl residue, designed to mimic the KGD (Lys-Gly-Asp) sequence that binds specifically to the platelet GP IIb/IIIa receptor.
Other Ingredients (Excipients)
- Citric acid monohydrate – used as a buffering agent to maintain the pH of the solution
- Sodium hydroxide – used for pH adjustment
- Water for injections – the solvent for the solution
Appearance and Packaging
Eptifibatide Accord 0.75 mg/ml solution for infusion is supplied as a clear, colourless liquid in a 100 ml glass infusion vial. The vial is sealed with a butyl rubber stopper and secured with a peel-off aluminium crimp cap. Each pack contains one infusion vial.
Marketing Authorisation Holder and Manufacturer
The marketing authorisation for Eptifibatide Accord is held by Accord Healthcare S.L.U., Barcelona, Spain. The product is manufactured at Accord Healthcare facilities in Poland and Greece. Eptifibatide Accord is authorised for use across the European Union through the European Medicines Agency (EMA) centralised procedure.
Frequently Asked Questions About Eptifibatide Accord
Eptifibatide is a potent antiplatelet medication that works by blocking the glycoprotein IIb/IIIa receptor on the surface of platelets. This receptor is the final common pathway for platelet aggregation – by blocking it, eptifibatide prevents platelets from clumping together and forming dangerous blood clots. It is used intravenously in hospitals for patients with acute coronary syndrome (heart attack or unstable angina) and those undergoing coronary stent procedures.
The standard treatment duration is up to 72 hours for acute coronary syndrome. If a percutaneous coronary intervention (PCI) such as stenting is performed during treatment, the infusion may be continued for up to 96 hours. The exact duration is determined by your cardiologist based on your clinical response, the procedures performed, and your individual risk factors.
No, eptifibatide works differently from aspirin and clopidogrel. While all three are antiplatelet agents, they target different pathways. Aspirin blocks the COX-1 enzyme, clopidogrel blocks the P2Y12 receptor, and eptifibatide blocks the GP IIb/IIIa receptor – the final common pathway of platelet aggregation. Eptifibatide is given intravenously in hospital, whereas aspirin and clopidogrel are taken orally. Importantly, eptifibatide’s effect is reversible and wears off within hours, while clopidogrel’s effect lasts for days.
Eptifibatide can be used in patients with mild to moderate kidney impairment, but the infusion rate must be reduced from 2 micrograms/kg/min to 1 microgram/kg/min. In patients with severe renal impairment (creatinine clearance below 30 mL/min) or those on dialysis, eptifibatide is not recommended because the drug is primarily excreted by the kidneys and would accumulate to potentially dangerous levels.
If significant bleeding occurs, the eptifibatide infusion is stopped immediately. Because eptifibatide’s antiplatelet effect is reversible, platelet function typically returns to near-normal within 4–8 hours after discontinuation. This rapid reversibility is one of the key advantages of eptifibatide compared to irreversible GP IIb/IIIa inhibitors. In severe cases, platelet transfusion may be considered, along with standard measures to control bleeding such as direct pressure and fluid resuscitation.
Eptifibatide has been extensively studied in major randomised controlled trials. The PURSUIT trial (over 10,000 patients) demonstrated a significant reduction in the composite endpoint of death or non-fatal myocardial infarction in ACS patients. The ESPRIT trial confirmed efficacy in PCI with coronary stenting, showing a 37% relative risk reduction in ischaemic events. These trials form the basis for eptifibatide’s inclusion in ESC and AHA/ACC guidelines for the management of acute coronary syndromes.
References
- The PURSUIT Trial Investigators. Inhibition of Platelet Glycoprotein IIb/IIIa with Eptifibatide in Patients with Acute Coronary Syndromes. N Engl J Med. 1998;339(7):436-443. doi:10.1056/NEJM199808133390704
- O’Shea JC, et al. Platelet Glycoprotein IIb/IIIa Integrin Blockade with Eptifibatide in Coronary Stent Intervention: The ESPRIT Trial. JAMA. 2001;285(19):2468-2473. doi:10.1001/jama.285.19.2468
- European Medicines Agency (EMA). Eptifibatide Accord – Summary of Product Characteristics. Available at: https://www.ema.europa.eu
- Collet JP, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42(14):1289-1367. doi:10.1093/eurheartj/ehaa575
- Lawton JS, et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization. J Am Coll Cardiol. 2022;79(2):e21-e129. doi:10.1016/j.jacc.2021.09.006
- World Health Organization (WHO). Model List of Essential Medicines, 23rd List. Geneva: WHO; 2023.
- British National Formulary (BNF). Eptifibatide. NICE Evidence Services. Available at: https://bnf.nice.org.uk
- Bhatt DL, Topol EJ. Current Role of Platelet Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes. JAMA. 2000;284(12):1549-1558. doi:10.1001/jama.284.12.1549
Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, comprising board-certified physicians specialising in cardiology, interventional cardiology, clinical pharmacology, and cardiovascular medicine.